Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapeutic Viltepso (viltolarsen) has managed to build a growing sales position in the US market over the five years since its launch, despite clinical setbacks and legal challenges involving the main player in the sector.
Viltepso Carves US DMD Position Despite Headwinds
Nippon Shinyaku has revised upward its US sales forecast for DMD drug Viltepso, which has overcome multiple challenges in building its position in the US.
